EQL PHARMA AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 47.2 SEK | +1.29% |
|
+9.01% | +41.32% |
| May. 15 | Transcript : EQL Pharma AB, Q4 2024 Earnings Call, May 15, 2024 | |
| May. 14 | Eql Pharma AB Provides Sales Guidance for the Year 2024/25 | CI |
| Sales 2024 | 264M 24.77M | Sales 2025 * | 367M 34.42M | Capitalization | 1.37B 129M |
|---|---|---|---|---|---|
| Net income 2024 | 22M 2.06M | Net income 2025 * | 54M 5.06M | EV / Sales 2024 | 5.03 x |
| Net Debt 2024 | 99.62M 9.34M | Net Debt 2025 * | 85M 7.97M | EV / Sales 2025 * | 3.97 x |
| P/E ratio 2024 |
55.7
x | P/E ratio 2025 * |
25.4
x | Employees | 19 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
Latest transcript on EQL Pharma AB
More press releases
| 1 day | +1.29% | ||
| 1 week | +9.01% | ||
| Current month | +8.76% | ||
| 1 month | +8.76% | ||
| 3 months | +21.96% | ||
| 6 months | +40.90% | ||
| Current year | +41.32% |
1 week
42.90
47.70
1 month
38.4047.70
Current year
33.0047.70
1 year
24.7047.70
3 years
23.0048.70
5 years
9.5048.70
10 years
2.8048.70
| Managers | Title | Age | Since |
|---|---|---|---|
Axel Schörling
CEO | Chief Executive Officer | 38 | 18-01-31 |
| Founder | 59 | 05-12-31 | |
Anna Jönsson
DFI | Director of Finance/CFO | 40 | 21-12-14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 59 | 05-12-31 | |
| Director/Board Member | 64 | 14-12-31 | |
| Director/Board Member | 51 | 19-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-24 | 47.2 | +1.29% | 13,337 |
| 24-05-23 | 46.6 | -1.89% | 42,815 |
| 24-05-22 | 47.5 | +2.37% | 32,999 |
| 24-05-21 | 46.4 | +3.11% | 15,826 |
| 24-05-20 | 45 | +3.93% | 11,254 |
End-of-day quote NORDIC GROWTH MARKET, May 23, 2024
More quotes
EQL Pharma AB is a Sweden-based Company that operates as a generic drugs and specialty pharmaceutical company. The Company engages in marketing, distributing, and selling generic drugs and specialty pharmaceuticals. Its main products are Anastrozol, Venlafaxin, Carvedilol, Metformin, Sumatriptan, Mometason, Glepark, among others. The company operates in Sweden and in Scandinavia.
Sector
Drug Retailers
Calendar
2024-08-12
- Q1 2025 Earnings Release (Projected)
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.32% | 129M | |
| -38.61% | 13.83B | |
| -31.33% | 10.96B | |
| +13.51% | 6.34B | |
| -8.33% | 6.08B | |
| -30.66% | 6.05B | |
| +72.00% | 5.04B | |
| -1.61% | 4.67B | |
| -4.84% | 4B | |
| -16.14% | 3.28B |
- Stock Market
- Equities
- EQL Stock
